Toxins 2013, 5(3), 524-536; doi:10.3390/toxins5030524
Article

Safety of Botulinum Toxin A in Children and Adolescents with Cerebral Palsy in a Pragmatic Setting

1 Department of Neurology, Pendeli Children's Hospital, 8 Hippokrates street, Palaia Penteli 15236, Athens, Greece 2 Department of Orthopedics, Pendeli Children's Hospital, 8 Hippokrates street, Palaia Penteli 15236, Athens, Greece
* Author to whom correspondence should be addressed.
Received: 17 January 2013; in revised form: 20 February 2013 / Accepted: 4 March 2013 / Published: 12 March 2013
PDF Full-text Download PDF Full-Text [198 KB, uploaded 12 March 2013 15:35 CET]
Abstract: This retrospective study aimed to examine the safety of botulinum toxin A (BoNT-A) treatment in a paediatric multidisciplinary cerebral palsy clinic. In a sample of 454 patients who had 1515 BoNT-A sessions, data on adverse events were available in 356 patients and 1382 sessions; 51 non-fatal adverse events were reported (3.3% of the total injections number, 8.7% of the patients). On five occasions, the adverse reactions observed in GMFCS V children were attributed to the sedation used (rectal midazolam plus pethidine; buccal midazolam) and resulted in prolongation of hospitalization. Of the reactions attributed to the toxin, 23 involved an excessive reduction of the muscle tone either of the injected limb(s) or generalized; others included local pain, restlessness, lethargy with pallor, disturbance in swallowing and speech production, seizures, strabismus, excessive sweating, constipation, vomiting, a flu-like syndrome and emerging hypertonus in adjacent muscles. Their incidence was associated with GMFCS level and with the presence of epilepsy (Odds ratio (OR) = 2.74 − p = 0.016 and OR = 2.35 − p = 0.046, respectively) but not with BoNT-A dose (either total or per kilogram). In conclusion, treatment with BoNT-A was safe; adverse reactions were mostly mild even for severely affected patients. Their appearance did not necessitate major changes in our practice.
Keywords: cerebral palsy; spasticity; treatment; botulinum toxin A; onabotulinumtoxin A; abobotulinumtoxin A; adverse events; safety

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Papavasiliou, A.S.; Nikaina, I.; Foska, K.; Bouros, P.; Mitsou, G.; Filiopoulos, C. Safety of Botulinum Toxin A in Children and Adolescents with Cerebral Palsy in a Pragmatic Setting. Toxins 2013, 5, 524-536.

AMA Style

Papavasiliou AS, Nikaina I, Foska K, Bouros P, Mitsou G, Filiopoulos C. Safety of Botulinum Toxin A in Children and Adolescents with Cerebral Palsy in a Pragmatic Setting. Toxins. 2013; 5(3):524-536.

Chicago/Turabian Style

Papavasiliou, Antigone S.; Nikaina, Irene; Foska, Katerina; Bouros, Panagiotis; Mitsou, George; Filiopoulos, Constantine. 2013. "Safety of Botulinum Toxin A in Children and Adolescents with Cerebral Palsy in a Pragmatic Setting." Toxins 5, no. 3: 524-536.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert